Peritoneal dialysis in lupus nephritis: comparative outcomes vs. hemodialysis, risk stratification, and modality selection framework.

Sleep health notes

Sleep health notes will be added by the Sleepatch editorial team.

中文解读

中文解读待补充：本站会优先为失眠研究、睡眠质量改善、昼夜节律等高价值睡眠研究添加中文说明。

Original abstract

Peritoneal dialysis (PD) is an effective and safe renal replacement therapy (RRT) for lupus nephritis (LN) patients with acute kidney injury (AKI) or end-stage renal disease (ESRD). This narrative review compares PD and hemodialysis (HD) in LN across both AKI and ESRD settings, highlighting differences in survival, cardiovascular outcomes, infection risk, and lupus flare incidence. We summarize clinical evidence demonstrating the preservation of residual renal function (RRF), hemodynamic stability, and improved cardiovascular tolerance associated with PD, while also noting challenges such as higher peritonitis susceptibility in chronically immunosuppressed patients. A structured risk stratification framework is presented to aid selection between PD and HD based on cardiac comorbidities, RRF, infection risk, catabolic state, pediatric status, and ability to perform home-based therapy. In addition, we outline a clinical decision algorithm to guide modality selection and discuss immunosuppressive strategies in PD-treated LN patients. Despite comparable mortality between PD and HD in most studies, PD may offer superior cardiovascular protection and lower flare risk in selected LN phenotypes. Early identification of ideal PD candidates, individualized prescription strategies, and multidisciplinary management are crucial to optimizing outcomes. This review provides a practical comparative synthesis, a decision-making framework, and future perspectives to support clinicians managing LN patients requiring dialysis.

Links and sources

• Official / arXiv page

Comments